Study Finds Gender-Affirming Care for Transgender Youth Rarer Than Perceived

Amidst a heated national debate over transgender youth healthcare, a new study offers crucial data, revealing that fewer than 1 in 1,000 adolescents with commercial insurance received gender-affirming medications in recent years.

The study, published Monday in a leading medical journal, provides the most reliable estimate to date on the prevalence of puberty blockers and hormone therapy among transgender youth. This comes as at least 26 states have enacted laws restricting or banning such care for minors, with legal challenges mounting and a pivotal Supreme Court decision on the horizon.

“We are not seeing inappropriate use of this sort of care,” said lead author Landon Hughes,a Harvard university public health researcher. “And it’s certainly not happening at the rate at which people often think it is.”

The research team analyzed a vast insurance claims database encompassing over 5 million patients aged 8 to 17 across all 50 states. Notably, the study found that no patients under age 12 were prescribed hormones, suggesting doctors are exercising appropriate caution regarding the timing of such treatments.

“I hope that our paper cools heads on this issue and ensures that the public is getting a true sense of the number of people who are accessing this care,” Hughes added.

While the database included various commercial insurance plans, it did not encompass youth covered by Medicaid, the federal-state health insurance program for low-income individuals. the study did not examine surgical procedures among transgender adolescents. However,previous research has indicated that such procedures are exceedingly rare among young people.

Dr. Scott Leibowitz, co-lead author of the adolescent standards of care for the World Professional Association for transgender Health, emphasized that not all transgender youth pursue medical interventions.

“Transgender adolescents come to understand their gender at different times and in different ways,” he explained. “The best care should include experts in adolescent identity growth who can work with families to help figure out what’s appropriate for each young person.”

Leibowitz, who has worked in gender clinics in several U.S. cities, believes the study contributes valuable evidence to the ongoing conversation surrounding best practices for supporting transgender and gender diverse youth.

A Conversation Starter

The study’s findings have sparked conversations across the country.

Jenna and Liam, two friends catching up over coffee, discussed the study’s implications.

Jenna: Hey Liam, have you heard about that new study on transgender youth and gender-affirming care?

liam: I saw something about it scrolling through my news feed, but I didn’t really have time to read it. What was it about?

Jenna: It’s pretty captivating. It basically says that gender-affirming care, like puberty blockers and hormones, is a lot rarer among teenagers than people think. The study looked at insurance claims for over 5 million kids across the country and found that less than 1 in 1,000 adolescents with private insurance received these medications.

Liam: Wow,really? I thought it was much more common than that,especially with all the debate around it lately.

Jenna: Me too! But the lead researcher, Landon Hughes from Harvard, said the data shows that doctors are being cautious and aren’t prescribing these medications unless they’re absolutely necessary. In fact, he pointed out that no kids under 12 were prescribed hormones.

Liam: That makes sense. It seems like there’s a lot of misinformation out there about what’s actually happening.

Jenna: Exactly. And this study is coming at a crucial time as so many states are trying to restrict access to this kind of care for teenagers. It’s vital to have accurate data to inform these conversations.

Liam: So what happens next? Will this study change anything?

Jenna: Well, it’s hard to say without a doubt, but Dr. Scott Leibowitz, another expert on transgender health, thinks it could help. He said it provides valuable evidence about best practices for supporting transgender youth, and hopefully, it can help cool down some of the heated rhetoric surrounding this issue.

Liam: That would be great. It truly seems like a topic that really needs some calm and thoughtful discussion.

Jenna: Definitely. It’s about the well-being of young people, and we owe it to them to get this right.

Study: Gender-Affirming Care for Transgender Youth Rarer Than Perceived

Amidst a firestorm of national debate surrounding transgender youth healthcare, a new study sheds light on the actual prevalence of gender-affirming care for this vulnerable population. Challenging prevailing assumptions, the research reveals that fewer than 1 in 1,000 adolescents with commercial insurance received medications like puberty blockers or hormone therapy in recent years.

Published Monday in a leading medical journal, this groundbreaking study offers the most reliable estimate to date on the use of gender-affirming medications among transgender youth. The findings arrive at a critical juncture, as at least 26 states have enacted legislation restricting or outright banning such care for minors. Legal battles are raging, and a pivotal Supreme Court decision looms on the horizon.

“Not Inappropriate Use”

Landon Hughes, the lead author and a public health researcher at Harvard University, underscored the study’s key finding: “We are not seeing inappropriate use of this sort of care.And it’s certainly not happening at the rate at which people often think it is.”

Hughes’ team meticulously analyzed a vast insurance claims database encompassing over 5 million patients aged 8 to 17 across all 50 states. Notably, the study found that no patients under age 12 were prescribed hormones, suggesting that doctors are exercising appropriate caution regarding the timing of such interventions.

Hope for a “Cooler” debate

“I hope that our paper cools heads on this issue and ensures that the public is getting a true sense of the number of people who are accessing this care,” Hughes added optimistically.

While the database included various commercial insurance plans, it did not encompass youth covered by Medicaid, the federal-state health insurance program for low-income individuals. Additionally, the study did not examine surgical procedures among transgender adolescents.

This research offers a much-needed dose of data-driven insight into a highly charged topic. As the legal and political battles rage on, the findings of this study could prove instrumental in informing a more nuanced and ultimately more compassionate public discourse.